Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Abstract Background Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expressing programmed death ligand 1 (PD-L1). Methods Patients with advanced...

Full description

Bibliographic Details
Main Authors: Janice M. Mehnert, Andrea Varga, Marcia S. Brose, Rahul R. Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Cancer
Subjects:
Thyroid cancer
Immunotherapy
Pembrolizumab
Anti–PD-1
PD-1
PD-L1
Online Access:http://link.springer.com/article/10.1186/s12885-019-5380-3

Internet

http://link.springer.com/article/10.1186/s12885-019-5380-3

Similar Items